jurgenfr
Shares of Viking Therapeutics (NASDAQ:VKTX) slid 8% post-market after the biotech company issued its Q4 earnings report and a pipeline update.
Viking reported a net loss of $0.32 per share with no revenue. Analysts, on average, had been expecting a net loss of $0.27 per